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Summary The Cyfra 21.1 assay is a newly developed test which measures in serum a fragment ofcytokeratin
19. We evaluated this marker in 212 patients with non-small-cell lung cancer (NSCLC), predominantly stage
3a-b and 4, and compared it with three other markers: carcinoembryonic antigen (CEA), squamous cell
carcinoma antigen (SCC) and tissue polypeptide antigen (TPA). Sensitivities for Cyfra 21.1, TPA, CEA and
SCC (using cut-off levels corresponding to a 95% specificity for benign lung diseases) were 40%, 40%, 42%
and 19% respectively. The sensitivity of CEA was significantly higher in patients with adenocarcinomas
compared with the other three markers, while the sensitivity of Cyfra 21.1 and TPA was significantly higher in
patients with squamous cell carcinomas. The value of Cyfra 21.1 for monitoring disease during chemotherapy
could be evaluated in 23 patients with squamous cell carcinomas. When the cases of lead time were included a
concordance between clinical evaluations according to WHO response criteria and evaluations according to
changes in the marker levels of 74% was found. The criteria defined for marker response were a 65% decrease
in the marker level for a partial response and a 40% increase for progressive disease. In particular, increasing
levels of this marker indicated usually disease progression. In conclusion, Cyfra 21.1 is a useful serum marker
for patients with NSCLC, especially for disease monitoring of patients with squamous cell carcinoma during
and after chemotherapy.
The clinical applicability of serum tumour markers in
patients with non-small-cell lung cancer (NSCLC) seems
limited. The available markers are not able to discriminate
between operable and inoperable disease and their sensitivity
and specificity are not high enough to justify a screening
programme (Minna et al., 1989; Bates, 1991). Moreover, the
number of reports about the value of serum tumour markers
for disease monitoring of patients with NSCLC during
chemotherapy and follow-up is small. Many patients with
NSCLC present with advanced disease, and for at least some
of these patients treatment with chemotherapy will be con-
sidered. The possible benefit of chemotherapy in these
patients is small and limited to only a few (Souquet et al.,
1993). Therefore treatment has to be evaluated carefully in
order to prevent continuation of ineffective treatment and
related toxicity for non-responding patients. Evaluation of
treatment in lung cancer according to standard WHO criteria
is often hampered by lack of measurable lesions because the
tumour is obscured by a pleural effusion or a concomitant
atelectasis or, sometimes, only bone lesions are present. Even
in the presence of measurable lesions the bulk of the disease
may be represented by non-evaluable lesions. Especially for
such cases the availability of a reliable tumour marker that
reflects the changes of the total tumour load would be helpful
to monitor treatment.
The Cyfra 21.1 assay is a test that has been recently
developed for the detection of a cytokeratin 19 fragment in
serum. The aim of the present study was to evaluate the
sensitivity of this new tumour marker in patients with
NSCLC. The sensitivity ofCyfra 21.1 was compared with the
sensitivity ofcarcinoembryonic antigen (CEA), squamous cell
carcinoma antigen (SCC) and tissue polypeptide antigen
(TPA).
Furthermore, we investigated the value of Cyfra 21.1 for
the monitoring of treatment in patients with squamous cell
lung cancer because a high sensitivity of Cyfra 21.1 has been
reported in this type of histology (Pujol et al., 1993). Finally,
a comparison was made between the Cyfra 21.1 immuno-
radiometric assay and an enzyme immunoassay developed by
Centocor and Boehringer Mannheim respectively.
Materials and methods
Patients
From 212 patients with histologically proven NSCLC, serum
samples were collected at diagnosis and during treatment
from those patients receiving chemotherapy. The samples
were stored at - 70°C until analysis. All patients were staged
according to the guidelines of the American Joint Committee
on Cancer (1988). Nodal status was confirmed histologically
or cytologically by mediastinoscopy, mediastinotomy or
thoractomy for those patients with stage Illa disease. Res-
ponse to chemotherapy was assessed according to standard
WHO (1979) criteria without knowledge of any tumour
marker level. The following response criteria for the tumour
markers were used: complete response, normalisation of an
elevated marker for at least 1 month; partial response,
decrease of 65% or more of an elevated marker for at least 1
month; stable disease, less than 65% decrease or less than
40% increase of an elevated marker; progressive disease,
more than 40% increase in an elevated marker level or a rise
from below to above the cut-off level (Bac et al., 1991).
These criteria are based on the assumption that the tumour
marker levels reflect three-dimensionally the total body
tumour load. A 50% decrease in a bidimensional measure-
ment (WHO criteria) then roughly corresponds to a 65%
decrease in a volumetric measurement, and a 25% increase in
a bidimensional measurement corresponds to a 40% increase
in a volumetric measurement. When both methods of evalua-
tion yielded the same result at the same time the evaluation
was called concordant.
Marker assessments
Serum Cyfra 21.1 assay values were determined using a
solid-phase double-determinant immunoradiometric assay
(Centocor Diagnostics, Malvern, PA, USA). This assay
utilises two monoclonal antibodies (KS 19.1 and BM 19.21)
reactive with different epitopes expressed by cytokeratin 19
fragments. KS 19.1 is coated on the solid phase and the BM
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19.21 antibody, radiolabelled with iodine-125, is used as the
tracer. For the correlation study Cyfra 21.1 assay values were
also measured by an enzyme immunological assay (Boehr-
inger Mannheim Immunodiagnostics, Tutzing, Germany).
This assay utilises the same two antibodies as the Centocor
IRMA assay, the tracer antibody being labelled with perox-
idase in the Boehringer Enzymun assay. Enzymun Cyfra 21.1
assay values were measured with a fully automated ES 600
analyser. CEA was measured using a commercial kit (CIS bio
international, Gif-Sur-Yvette, France), TPA with another
commercial kit (Prolifigen RIA Sangtec Medical, Bromma,
Sweden) and SCC with a commercial radioimmunoassay
from Abbot Diagnostika (Wiesbaden, Germany).
Cut-off values used in this study were 3.3 ng ml1 for
Cyfra 21.1, 170U1' for TPA, 7.4ngml-' for CEA and
2.4ngml-' for SCC. These cut-off values correspond to a
95% specificity for all markers determined in 546 patients
with non-malignant lung diseases (Rastel et al., 1993).
TPA and SCC and CEA, but not between CEA and SCC
(Table III). An example of a scatter diagram of Cyfra 21.1
and TPA is given in Figure 3.
Correlation between the Cyfra 21.1 radioimmunometric assay
and the Cyfra 21.1 enzyme immunoassay
A scatter diagram of the assay results of 200 different sam-
ples measured by the Cyfra 21.1 radioimmunometric assay
and the Cyfra 21.1 enzyme immunoassay is shown in Figure
4. After logarithmic transformation of the values, the correla-
tion coefficient between the two assays was 0.99.
Disease monitoring with Cyfra 21.1 in patients with squamous
cell lung carcinoma
Of the 80 patients with a squamous cell carcinoma, 49 (61%)
fulfilled the following criteria: (1) treated with chemotherapy;
Statistical methods
The variables Cyfra 21.1, SCC, CEA and TPA were log
transformed before calculation of correlation coefficients.
Correlation coefficients were assessed by simple linear regres-
sion analysis. For testing significance Student's t-test was
used. A P-value less than 0.05 was considered significant.
Results
Sensitivity
Patient characteristics are listed in Table I. The four tumour
markers were determined in all 212 patients. The median
assay value for Cyfra 21.1 was 2.0ngml' (range 0-1057),
for CEA 4.5 ng ml-' (range 0.2-3969), for TPA 122 U 1-'
(range 23-29121) and for SCC I.Ongml-' (range 0-141).
At least one elevated marker concentration was found in 146
patients (69%). When a combination of two markers was
used, 61% of the patients had an elevated CEA or TPA or
an elevated CEA or Cyfra 21.1. Thirty-one per cent of
patients had normal values for all four markers.
Higher median CEA values were found in patients with
adenocarcinomas than in patients with squamous cell car-
cinoma or large-cell undifferentiated carcinoma, whereas
higher median levels of Cyfra 21.1 and SCC were found in
patients with squamous cell carcinoma compared with the
other two histological types. The percentages ofpatients with
a marker level above the cut-off level for all patients accord-
ing to different histological type are listed in Table II. The
sensitivity of the four markers by stage IlIa, IIIb and IV is
shown in Figure 1. The sensitivity of the markers in
squamous cell carcinoma according to the different stages is
shown in Figure 2.
A significant inter-marker correlation was observed between
Cyfra 21.1 and CEA, between TPA and SCC, and between
Table II Sensitivity ofCEA, TPA, SCC and Cyfra 21.1 in 212 patients







All patients (212) 42 40 19 40
Adeno (65) 62 37 9 35
Large-cell (67) 37 33 13 31
undifferentiated
Squamous cell (80) 30 47 32 52
Cut-off values: CEA 7.4 ngml-'; TPA 170 UI-'; SCC 2.4 ngml-';













Figure 1 Sensitivity by stage for all histologies. Stage lIla,
n = 59; stage IlIb, n = 37; stage IV, n = 109.
Table I Patient characteristics




Median age (years) (range) 59 (29-81)









Squamous cell carcinoma 80 (38%)







Figure 2 Sensitivity by stage for squamous cell carcinoma. Stage
Illa, n = 33; stage IlIb, n = 13; stage IV, n = 31.CYFRA 21.1 IN NON-SMALL-CELL LUNG CANCER 527
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Figure 3 Scatter diagram of TPA vs Cyfra 21.1.
TableIII Correlationsbetweenthemarkersafterlogarithmictransfor-
mation of the values (n = 212)
CEA TPA SCC Cyfra
CEA 1 0.28 0.04 0.26
TPA (0.0000) 1 0.27 0.92
SCC (0.56) (0.0000) 1 0.31
Cyfra 21.1 (0.0001) (0.0000) (0.0000) 1
Significance level is shown in parentheses.
(2) marker determinations at the moment of clinical evalua-
tion for response to chemotherapy, usually 3 or 4 weeks after
the last course of chemotherapy; and (3) measurable lesions.
In these patients serum levels of Cyfra 21.1 were retrospec-
tively analysed and subsequently compared with the results
ofthe clinical evaluations of response. Response was assessed
every other cycle of chemotherapy, unless there was clinical
evidence of rapidly progressive disease, in which case res-
ponse evaluation was performed earlier.
The median number of samples taken during and after
chemotherapy for these patients was 5 (range 2-17). The
clinical characteristics of this subgroup ofpatients are shown
in Table IV. Forty-two patients were treated with combina-
tion chemotherapy consisting of cisplatin and etoposide or
teniposide and seven patients were treated with single-agent
chemotherapy consisting of teniposide, carboplatin or nimus-
tine. Twenty-three patients (47%) had an elevated level of
Cyfra 21.1 (>3.3 ngml') at the start of treatment. Of the
26 patients with a normal level at the start of treatment, five
patients had an increase in Cyfra 21.1 above the cut-off level
during follow-up, in most instances during the end stage of
the disease. However, not all patients had samples taken after
the end ofchemotherapy. In the 23 patients with an elevated
Cyfra 21.1 and evaluable lesions, 57 evaluations for response
were performed. The concordance between the results of the
clinical evaluations according to WHO criteria and the
changes in the marker according to the earlier mentioned
criteria was 65%. Four of the 20 discordant evaluations
could be explained by a positive lead time of the marker, i.e.
the change in the tumour marker preceded the results
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Figure 4 Scatter diagram of the results of two assays for Cyfra
21.1.
Table IV Patients with a squamous cell carcinoma with a sufficient
number ofmarker determinations during and after treatment





Median age (years) (range) 61 (44-71)







obtained by the clinical evaluation by 1 or 2 months. On
three of these four occasions the marker indicated that
disease progression had occurred while the clinical diagnosis
was still stable disease. The remaining event occurred in a
patient in whom normalisation of the marker and clinically
stable disease was followed by a partial response. A negative
lead time was observed on one occasion in a patient with
progressive disease in whom the tumour marker met the
criteria for progressive disease only 4 weeks later.
In ten cases the clinical response was partial response while
Cyfra 21.1 levels had dropped below the cut-off level. In
three evaluations the clinical evaluation was of stable disease
although tumour regression was observed and a partial res-
ponse of the marker was observed on one occasion and a
complete response of the marker on t,wo occasions.
In one patient the marker indicated progression but the
clinical evaluation was stable disease. This patient was subse-
qently treated with radiotherapy so that the possibility of a
positive lead time of the marker could not be assessed.
On one occasion the marker level increased when clinical
progression was documented but not sufficiently to meet the
criteria set for marker progression. A summary of the discor-
dant evaluations is given in Table V.528 A. VAN DER GAAST et al.
Table V Discordant evaluations of Cyfra 21.1
Total number of evaluations 57
Number of discordant evaluations 20
Positive lead time 4
Negative lead time 1
Partial response according to WHO/complete response 10
marker
Stable disease according to WHO (tumour regression 3
<50%)/partial or complete response marker
Stable disease according to WHO/progressive disease 1
marker
Progressive disease according to WHO/stable disease 1
marker (marker increase less than 40%)
Discussion
Cytokeratins are cytoskeletal intermediate filaments present
in almost all normal and malignant epithelial cells. Charac-
teristic combinations of cytokeratin polypeptides are ex-
pressed in different epithelia depending on their origin or
type of differentiation (Moll et al., 1982). The principal func-
tion of most intermediate filaments is most likely to provide
mechanical support to the cell and its nucleus (Geiger, 1987).
In this study we first investigated the value of the newly
developed marker Cyfra 21.1 in patients with non-small-cell
lung cancer and compared it with three other tumour
markers: CEA, SCC and TPA. As can be seen in Table II the
overall sensitivity of Cyfra 21.1 was similar to the sensitivity
of CEA and TPA but significantly higher than the sensitivity
of SCC. This is also true for patients with large-cell lung
carcinoma. In patients with adenocarcinomas the sensitivity
of CEA was significantly higher than the sensitivity of the
three other markers tested, while in patients with squamous
cell carcinoma Cyfra 21.1 had the highest sensitivity although
not significantly higher than the sensitivity of TPA. Although
the overall sensitivity of Cyfra 21.1 in the studied group,
including most patients with advanced disease, was 40%, it
can be anticipated that this is far too low for screening
purposes. An increased sensitivity was found in the higher
stages, but considerable overlap is observed between the
various stages.
It is interesting to speculate why the sensitivity of Cyfra
21.1 is higher in patients with squamous cell carcinoma than
in patients with adenocarcinoma. Since cytokeratins are
generally released during cell death, this suggests either that
the content of cytokeratin 19 in squamous carcinoma cells is
higher than in adenocarcinoma cells or that the cell loss
factor is larger in patients with squamous cell carcinoma.
Although cytokeratin 19 is widely distributed in epithelial
tissues and generally regarded as characteristic of simple
epithelia, a relation with the keratinocyte keratins has been
suggested (Bartek et al., 1985; Stasiak et al., 1989). The fact
that the sensitivity of TPA is also higher in patients with
squamous cell carcinoma than in patients with adenocar-
cinoma argues against the hypothesis that the increased sen-
sitivity is only related to squamous cell differentiation. A
highly significant inter-marker correlation was found, especi-
ally between TPA and Cyfra 21.1. This observation may
suggest that these two markers are related to the same cells
or bear the same relationship with the total tumour load.
The value of Cyfra 21.1 for disease monitoring could be
evaluated in 23 patients. When the cases with lead time were
included a concordance between clinical evaluation according
to WHO response criteria and evaluation according to
changes in the marker levels of 74% was observed. Most of
the discordant evaluations were caused by patients who
achieved minor regression or a partial response to chemo-
therapy while the marker level dropped below the cut-off
level. When the cases in which the clinical evaluation was
partial response while a normalisation of the marker took
place were alone not considered to be discordant, the percen-
tage of discordant evaluations drops to 9%. Progression of
the marker with clinical stable diseasae was observed only
once. The possible explanation for this occurrence was a
positive lead time of the marker in a patient with stable
disease who was not evaluable for further response evalua-
tion because of subsequent radiotherapy. In all the other
cases a 40% increase in the level of Cyfra 21.1 indicated
disease progression.
In conclusion, Cyfra 21.1 seems to be a valuable tumour
marker for disease monitoring at least in patients with
squamous cell lung cancer, especially since increasing levels
of this marker usually indicated disease progression, and
such knowledge obtained in an easy way may prevent con-
tinuation of ineffective toxic treatment.
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